Form 4: Immunome Director Isaac Barchas Granted Long-Term Stock Options

Immunome Inc. Director Isaac Barchas was granted 18,864 stock options with an exercise price of $9.57, vesting quarterly over one year starting June 10, 2025.

Summary

• Isaac Barchas, a Director of Immunome Inc. (IMNM), was granted 18,864 stock options.
• The options have an exercise price of $9.57 per share.
• The vesting period for these options begins on June 10, 2025, and occurs in four quarterly installments until the one-year anniversary thereafter.
• Full vesting is contingent upon Mr. Barchas's continuous service with the company on each respective vesting date.
• The options expire on June 9, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive sign, indicating alignment of interests and a long-term commitment. It's a standard compensation practice, so not overwhelmingly positive, but certainly not negative.

Positives

• The granting of stock options to a director aligns their interests with shareholders, incentivizing long-term performance and retention.
• The options have a 10-year expiration period, providing a long window for potential value realization.

Negatives

• The value of the options is tied to future stock appreciation, as the exercise price of $9.57 is the grant price, not a discounted rate.

Risks

• The value of the options is dependent on the future stock price of Immunome Inc. exceeding the exercise price of $9.57.
• Vesting is subject to continuous service, meaning the options could be forfeited if the director leaves the company before full vesting.

Future Outlook

The granting of these stock options indicates a long-term incentive for Director Isaac Barchas, aligning his future compensation with the company's stock performance over the next decade, subject to continued service and quarterly vesting through June 2026.

Industry Context

Stock option grants are a common form of executive and director compensation in the biotechnology and pharmaceutical industries, aiming to attract and retain talent by linking their financial incentives to the company's long-term success and shareholder value creation. This practice is standard across the industry for incentivizing key personnel.

Comparison to Industry Standards

• This type of equity grant, specifically stock options with a multi-year vesting schedule and a 10-year expiration, is a standard compensation practice for directors in the biotechnology sector.
• Companies like Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) frequently use similar long-term incentive plans to align director interests with shareholder value.
• The specific number of options and exercise price would need to be compared against Immunome's market capitalization and peer group compensation benchmarks for a more detailed assessment, but the structure itself is typical.

Stakeholder Impact

• Shareholders: Potential dilution if options are exercised, but also potential for increased shareholder value if the director's incentives lead to improved company performance.

Next Steps

• Future Form 4 filings will report the exercise or sale of these options by Isaac Barchas.
• The options will vest in four quarterly installments, with the first vesting on June 10, 2025, and subsequent vestings occurring quarterly until June 10, 2026.

Key Dates

Recommendation

Keywords

Immunome Inc., IMNM, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Executive Compensation, Biotechnology, Pharmaceuticals